Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP-1454 in Advanced Solid Tumors and Anal Cancer
NCT04328740Phase 1Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Jul 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tp-1454 in solid tumor (advanced stage) and anal cancer, sponsored by Sumitomo Pharma America. Primary endpoints: Maximum Tolerated Dose at 50 months, Recommended Phase 2 Dose at 50 months and 1 more. Started Jul 2020; status: completed.
02
Drugs
tp-1454
03
Conditions
solid tumor (advanced stage)anal cancer
Beyond the preview
Go deeper on NCT04328740.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04328740.